Navigation Links
Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Date:2/5/2008

updated guidance with the SEC in a publicly accessible document. Clinical guidance in this news release is as of February 5, 2008.

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of AZ-007, the development of the Company's product candidates, projected clinical trial enrollment and data reporting timelines, and safety of the Company's products and technologies. Any statement describing a product candidate or Alexza's goals, expectations, intentions or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs that are intended to be safe and effective for use as therapeutics. Alexza's forward-looking statements also involve assumptions that, if they do not materialize or prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These statements are based only on facts and factors known by Alexza as of the date hereof. As a result, investors are cautioned not to rely on these forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings: "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them" and "We will need substantial additional capital in the future. If additional capital is not
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at June 30, ... March 31, 2014."The second half of 2014 will be an ... milestones for a number of our late-stage clinical programs," said ... "The first of these is the potential US and EU ...
(Date:7/31/2014)...  UBM Medica US announces that Cancer ... presents exclusive slide shows dealing with communication in the ... care. Cancer Network, the online ... blogs, and podcasts about the latest clinical findings. Among ... , End-of-life care is challenging for even the ...
(Date:7/31/2014)... July 31, 2014  Decision Resources Group is launching ... product Marketrack to now include ChinaTrack; the new capabilities ... in an interactive dashboard providing detailed brand-level share tracking ... a hospital level. Other key capabilities of ... feed: In addition to end-user surveys of healthcare facilities, ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Swiss Exchange: CRX) today announced that following the end of ... Johnson & Johnson has acquired 98.89% of the issued Shares ... Crucell) and 98.93% of the issued and outstanding Shares in ...
... Cellceutix Corporation (Pink Sheets: CTIX ) today ... Agreement (CDA) pertaining to its anti-cancer drug, Kevetrin™, with ... Cellceutix CEO, Leo Ehrlich, commented, "It,s relatively uncommon ... a compound before clinical trials are underway.  The process ...
Cached Medicine Technology:Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 2Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 3Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 4Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 5Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 6Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 7Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3
(Date:8/1/2014)... 2014 Online retailer Disposable Medical Express ... price guarantee on their inventory of Tranquility incontinence care ... and pads along with other personal care products. ... find a line of incontinence products that you love,” ... that works for you, you shouldn't have to compromise ...
(Date:8/1/2014)... 01, 2014 We are very ... on AWS Marketplace. EspressReport ES-AMI delivers enterprise grade ... $0.50 per hour (AWS infrastructure charges apply). , ... enterprise BI and operational reporting system with strong ... ad hoc reporting. It allows users to easily ...
(Date:8/1/2014)... Stress management can be difficult in this day ... and diminish rest and leisure time, stress can mount up ... find a way to manage stress in order to be ... a good sense of work-life balance is the key to ... clinician of SF Custom Chiropractic. “Stress, left unchecked, can not ...
(Date:8/1/2014)... Register to join the webinar here: ... years on record for life sciences investing. IPOs in the ... percent of all venture dollars spent in 2013. The result: ... , However, 2014 is proving more of a mixed ... Valley Bank, while life sciences IPOs are losing steam, M&A ...
(Date:7/31/2014)... 2014 Just in time for Washington’s ... is featuring new summertime drink specials on their ... Duke’s locations throughout the season. , A ... award-winning, customer-nominated Seattle’s best happy hour is well-known for ... Lake Union location’s 25th anniversary this summer, Duke is ...
Breaking Medicine News(10 mins):Health News:Disposable Medical Express Offering Low Price Guarantee On Tranquility Products 2Health News:Quadbase Systems Inc. Announces The Availability Of It’s Flagship Enterprise Reporting, Dashboard and BI Analytics Tool on Amazon’s AWS Marketplace 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3
... , TUESDAY, Nov. 29 (HealthDay News) --,When a friend lets them ... study suggests. It included 267 fourth- and fifth-grade students in ... in which a friend had violated a core expectation of friendship, ... to do their part on a joint school project. Girls ...
... , AUGUSTA, Ga. The same filtered light that ... ability to detect early signs of cervical cancer, reducing ... focused than traditional radial light which scatters in all ... physician and Director of the Gynecologic Cancer Prevention Center ...
... Using diffusion tensor imaging (DTI) to study the effects ... the ball with high frequency have brain abnormalities similar to ... their study were presented today at the annual meeting of ... in which players field the soccer ball with their head, ...
... family history of breast cancer are just as likely to ... history of the disease, according to a study presented today ... America (RSNA). These findings indicate that women in this age ... breast cancer screening guidelines issued by the U.S. Preventive Services ...
... journal Addiction demonstrates that even small changes in ... of violent incidents. The findings suggest that a one-hour extension ... average of 20 violent cases at night on weekends per ... of approximately 16 percent. The results suggest that ...
... perspective in addressing the supply of doctors and ... CMAJ ( Canadian Medical Association Journal ) ... and accurately predicting the response of physicians to ... the supply of physician services," writes Brian Golden, ...
Cached Medicine News:Health News:Polarized filter may reduce unnecessary cervical biopsies and surgeries 2Health News:'Heading' a soccer ball could lead to brain injury 2Health News:New study supports mammography screening at 40 2Health News:Norwegian study finds opening bars longer increases violence 2Health News:Paying physicians more to get more -- or to get less 2
... WH, the latest in the Magnes line of ... and its full cortical coverage, provides the highest ... allowing study of a wide range of neuronal ... choice of detector configurations and can be equipped ...
... a non-invasive and painless method of stimulating ... Laboratories manufactures two magnetic stimulation devices, the ... (HSMS). The Hight Speed MES-10 ... up to 25 Hz at full power. ...
... MOBEE headboxes are the ... line of portable battery-powered ... a robust new mechanical ... software, XLTEK's standard MOBEE24plus ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: